ストックスクリーナーアプリを入手
35.59
0.17%
0.06
アフターアワーズ：
35.64
0.05
+0.14%
前日終値:
$35.53
開ける：
$35.88
24時間の取引高:
164.33K
Relative Volume:
0.50
時価総額：
$1.70B
収益：
-
当期純損益:
$-111.48M
株価収益率:
-12.42
EPS:
-2.865
ネットキャッシュフロー:
$-88.09M
1週間 パフォーマンス:
+5.48%
1か月 パフォーマンス:
+5.99%
6か月 パフォーマンス:
+36.00%
1年 パフォーマンス:
+224.13%
1日の値動き範囲:
$34.84
$36.65
1週間の範囲:
$32.41
$36.65
52週間の値動き範囲:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
35.59 | 1.70B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Strong Buy |
| 2026-02-02 | 開始されました | Wells Fargo | Overweight |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG - Moomoo
Rapport Therapeutics advances RAP-219 after strong Phase 2a data - The Globe and Mail
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock By Investing.com - Investing.com India
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock - Investing.com UK
Rapport Therapeutics reports extended efficacy data for RAP-219 By Investing.com - Investing.com Australia
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock - MarketBeat
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
RAPP Reports Positive Results from Phase 2a Trial Follow-Up - GuruFocus
Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results - TradingView
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock - Investing.com
Rapport Therapeutics reports extended efficacy data for RAP-219 - Investing.com
Rapport Therapeutics reports sustained seizure reductions, 22-day half-life for RAP-219 in Phase 2a follow-up - TradingView
Rapport Therapeutics (RAPP) posts durable RAP-219 seizure cuts and details late-stage plans - Stock Titan
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting - The Manila Times
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2%Here's What Happened - MarketBeat
Rapport Therapeutics (RAPP) Stock Value Opportunity (On the Radar) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Is Rapport Therapeutics (RAPP) stock continuing its trend (Ticks Higher) 2026-04-18Public Sentiment - Xã Châu Thành
Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Brokered 10b5-1 sales listed for RAPP (NASDAQ: RAPP) - Stock Titan
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) CDO sells 19,865 shares under 10b5-1 plan - Stock Titan
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
What is the dividend outlook for Rapport Therapeutics (RAPP) Stock | Price at $34.13, Down 0.12%Expert Entry Points - Newser
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Rapport Therapeutics Inc (RAPP) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):